Continuous Glucose Monitor Billing 2026: HCPCS Supply Codes, the Supplier vs. Physician Split, and the Documentation Medicare Actually Requires

By Rcmaxis Revenue Cycle Team  ·  September 2026  ·  12 min read

Continuous glucose monitors have grown from a niche device for a small population of insulin-dependent patients into a mainstream diabetes management tool used across a much broader patient population, and that growth has outpaced a lot of practices' understanding of how CGM actually bills. It's tempting to lump CGM in with the remote patient monitoring code family most practices already know from managing other connected devices — but CGM supplies bill through their own distinct DME HCPCS codes, with their own coverage criteria, separate from the RPM CPT codes covering device setup and data review time for other conditions.

This guide covers the CGM-specific HCPCS codes and the supplier-versus-physician billing split, the testing-frequency and clinical documentation Medicare requires before approving and continuing coverage over time, and where CGM billing most often gets confused with — and incorrectly merged into — general remote monitoring billing.

CGM's Own Code Set — Separate From RPM

CGM supplies and the receiver device bill under their own HCPCS codes, distinct from the CPT code family (99453, 99454, 99457, 99458) used for general remote physiologic monitoring. Billing CGM supplies under the RPM codes, or vice versa, is a category error most claims-processing systems will reject, but some practices catch this only after a pattern of denials rather than checking the correct code family up front.

The K-code and A-code pathway applies when a DME supplier provides the device and ongoing monthly supplies directly to the patient, billed as a recurring supply allowance rather than a one-time charge. The 952xx codes, by contrast, apply when the physician practice itself is providing the device or performing the clinical interpretation of CGM data as a distinct professional service — and a practice doing both of these things at once (dispensing through an in-house DME arrangement and billing physician interpretation) needs to keep these two distinct billing roles clearly and consistently separated to avoid ever billing the same underlying component twice under two different code families.

The distinction between "adjunctive" and "non-adjunctive" CGM matters for code selection as well, and it's a distinction many practices don't realize affects billing at all. Adjunctive CGM requires the patient to confirm readings with a fingerstick test before making treatment decisions, while non-adjunctive CGM is approved for treatment decisions based on the sensor reading alone. Coverage policy and supply code assignment can differ between the two categories, so confirming which type of device a patient is actually using — not assuming based on the device manufacturer alone, since some companies offer both types — matters before selecting the billing code.

Medicare Coverage Criteria: Testing Frequency and Insulin Use

Medicare's coverage policy for therapeutic CGM sets specific clinical thresholds that have to be documented, not assumed from a general diabetes diagnosis. Coverage generally requires the patient to be on multiple daily insulin injections or an insulin pump, testing blood glucose four or more times daily, and requires the treating practitioner to have seen the patient within a specific recent window before ordering the device and periodically thereafter to assess ongoing adherence and treatment plan effectiveness.

A standard written order is also required before the first month of supplies can be billed, and that order needs to specify the device type, the frequency of supply replacement, and the length of need — a generic prescription simply stating "CGM as needed" doesn't meet the detailed written order standard DME claims require. Practices that treat the CGM order the same way they'd write a routine medication prescription, rather than as a DME order with its own specific documentation elements, are setting up the very first month of supply billing to fail on a technicality that has nothing to do with whether the patient actually qualifies.

The Face-to-Face Visit Requirement Practices Miss

Beyond the initial qualifying visit, Medicare requires ongoing periodic visits to assess whether the patient is actually using the CGM device as intended and whether the treatment plan is being adjusted based on the data it's generating — coverage isn't a one-time approval that continues indefinitely without any check-in. A practice that orders a CGM, gets it approved, and then doesn't schedule the required follow-up visit within the specified window is at risk of the ongoing supply billing being denied on a subsequent audit, even though the initial order was entirely appropriate.

Common CGM Denial Patterns and Fixes

• CGM supplies billed under RPM CPT codes instead of CGM-specific HCPCS codes: Fixed by routing CGM billing through K-codes/A-codes (supplier) or 952xx codes (physician interpretation), never the RPM code family.
• Insulin regimen and testing frequency not explicitly documented: Fixed by stating the specific regimen and testing frequency in the ordering visit note, not just the diabetes diagnosis.
• Missing periodic reassessment visit for ongoing supply coverage: Fixed by scheduling and documenting the required follow-up visit within Medicare's specified window, tracked proactively rather than reactively.
• Physician interpretation (95251) billed without a distinct interpretive report separate from the raw data: Fixed by documenting an actual clinical interpretation and treatment-plan response, not just noting that data was reviewed.

CGM billing is a case where the technology moved faster than most practices' billing training did — the device itself is now routine in diabetes management, but the specific supply-code and coverage-documentation requirements behind it haven't gotten the same attention as the clinical adoption. Practices that treat CGM as "just another diabetes supply" rather than its own distinct billing category, with its own code family and its own coverage documentation standard, are the ones generating the denial patterns above on a recurring basis rather than as an occasional exception. As CGM adoption keeps expanding beyond insulin-dependent patients into broader diabetes and even prediabetes management, getting this billing category right now — before volume grows further — is considerably easier than untangling a systemic coding error across a much larger patient panel later. The practices building that discipline in now, while CGM volume is still manageable, are the ones that won't be caught flat-footed when a routine DME review eventually turns its attention to this fast-growing corner of diabetes care — and given how quickly adoption is expanding across the diabetes population, that attention is realistically a matter of when, not if.